Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Tislelizumab +/- Lenvatinib in High-Risk HCC
NCT05910970Phase 3Not yet recruiting
- Sponsor
- Guangxi Medical University
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) comparing Adjuvant tislelizumab plus lenvatinib with Adjuvant tislelizumab (2 arms). Primary endpoint: Recurrence-free survival at 3 years. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
tislelizumablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05910970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05910970.